drugset / Trial / NCT04151277
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
Phase 2
Unknown
500 enrolled
Judith Dixon-Hughes
NHS Greater Glasgow and Clyde · collabUniversity of Glasgow · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG. Treatment will continue until progression or patient/clinican decision or intolerable toxicity.
Timeline
- Start
- 2017-11-28
- Primary completion
- 2025-12-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 350 mg | Intravenous |
| Comparator | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Comparator | Nab-paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |